Associated Papers
Regulation of Human Hydrolases and Its Implications in Pharmacokinetics and Pharmacodynamics.
Jung SM et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.
Liu Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2024
Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach.
Liu S et al.
Frontiers in Pharmacology, 2020
Clinical implications of genetic variation in carboxylesterase drug metabolism.
Chen F et al.
Expert Opinion on Drug Metabolism & Toxicology, 2018
Interindividual variability of carboxymethylenebutenolidase homolog, a novel olmesartan medoxomil hydrolase, in the human liver and intestine.
Ishizuka T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K et al.
British Journal of Clinical Pharmacology, 2010
Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Kim SR et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
Role of pharmacogenetics in irinotecan therapy.
de Jong FA et al.
Cancer Letters, 2006
Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
Kubo T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2).
Kim SR et al.
Drug Metabolism and Pharmacokinetics, 2003
Select a paper to view details